Alzheimer's Disease News and Research

RSS
Alzheimer's disease (AD) is an irreversible, progressive brain disease that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks of daily living. In most people with AD, symptoms first appear after age 60. AD is the most common cause of dementia among older people, but it is not a normal part of aging. Dementia refers to a decline in cognitive function that interferes with daily life and activities. AD starts in a region of the brain that affects recent memory, then gradually spreads to other parts of the brain. Although treatment can slow the progression of AD and help manage its symptoms in some people, currently there is no cure for this devastating disease.
Heptares exercises exclusive option to license new A2A antagonist for CNS disorders

Heptares exercises exclusive option to license new A2A antagonist for CNS disorders

Health must be taken into account in climate change mitigation strategies

Health must be taken into account in climate change mitigation strategies

Technique developed to identify rogue clustering proteins in brain diseases

Technique developed to identify rogue clustering proteins in brain diseases

Novel technique rapidly identifies and tracks location of diseased proteins inside cells

Novel technique rapidly identifies and tracks location of diseased proteins inside cells

Merz launches new, once daily Mederma Advanced Scar Gel

Merz launches new, once daily Mederma Advanced Scar Gel

Klf4 protein an important regulator of inflammation: HNK study

Klf4 protein an important regulator of inflammation: HNK study

Pfizer supports First World Congress on Healthy and Active Ageing

Pfizer supports First World Congress on Healthy and Active Ageing

SBMT announces 2012 recipients of Pioneers in Medicine, Technology and Healthcare Policy Awards

SBMT announces 2012 recipients of Pioneers in Medicine, Technology and Healthcare Policy Awards

ApoE4 gene could cause early loss of synapses in Alzheimer's disease

ApoE4 gene could cause early loss of synapses in Alzheimer's disease

SK Biopharmaceuticals initiates YKP10811 phase 2 trial in chronic constipation

SK Biopharmaceuticals initiates YKP10811 phase 2 trial in chronic constipation

Older women with mild retinopathy more likely to have cognitive decline and related vascular changes

Older women with mild retinopathy more likely to have cognitive decline and related vascular changes

Eight European research institutes partner to provide training on systemic neuroscience

Eight European research institutes partner to provide training on systemic neuroscience

Viewpoints: Health costs crushing Detroit; Military care still faces funding issues; Romneycare scores

Viewpoints: Health costs crushing Detroit; Military care still faces funding issues; Romneycare scores

Women with retinopathy more likely to have cognitive problems

Women with retinopathy more likely to have cognitive problems

New UCLA Alzheimer's and Dementia Care program for patients, caregivers

New UCLA Alzheimer's and Dementia Care program for patients, caregivers

New RAGE inhibitor shows promise against Alzheimer's

New RAGE inhibitor shows promise against Alzheimer's

State roundup: Caregivers face 'burnout' threat as need grows, Kansas nursing home staff inadequate?

State roundup: Caregivers face 'burnout' threat as need grows, Kansas nursing home staff inadequate?

Potential new way to treat rare inherited metabolic disorders

Potential new way to treat rare inherited metabolic disorders

Microbubbles and focused ultrasound help drugs enter the brain

Microbubbles and focused ultrasound help drugs enter the brain

Scientists gain insight into why lithium salts are effective at treating bipolar disorder

Scientists gain insight into why lithium salts are effective at treating bipolar disorder

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.